LucentAD® Complete

Casandra

Casandra Test Code LU20955Version 1 (DRAFT)

Performing Lab

Lab Lucent DiagnosticsLab Test ID N/A

Clinical Use

Use

LucentAD® Complete is a multi-biomarker blood test designed to assess Alzheimer's disease pathology by measuring Alzheimer's-related biomarkers. The test reduces diagnostic uncertainty by combining four critical biomarkers: p-Tau 217, AB42/40, GFAP, and NfL. This comprehensive panel provides a complete risk assessment for amyloid pathology, enabling earlier and more accurate diagnosis of Alzheimer's disease. The use of these specific biomarkers improves the accuracy of amyloid status classification and reduces the gray diagnostic zone, providing definitive results for more patients.

Special Instructions

The assay is currently not available in New York State. It is a non-invasive, blood-based diagnostic tool that complements other diagnostic modalities. The test is intended for use as part of a clinical evaluation, and results should be interpreted within the context of a comprehensive diagnostic assessment.

Limitations

LucentAD® Complete has not been cleared or approved by the U.S. Food and Drug Administration. Results obtained with the test should be used in conjunction with other diagnostic procedures and clinical assessments. While the test helps assess amyloid pathology likelihood, it is not standalone and should not be solely relied upon for Alzheimer's disease diagnosis.

Test Details

Methodology

Immunoassay (Multiplex Protein Panel)

Biomarkers

4 targets

AB42/40 RatioGlial Fibrillary Acidic Protein (GFAP)Neurofilament Light (NfL)p-Tau 217

Result Turnaround Time

10 days

Specimen

Plasma

Volume

1 mL

Minimum Volume

0.5 mL

Container

Pearl-top tube, gel barrier tube

Collection Instructions

Draw blood in a pearl-top (K2 EDTA) tube. Invert to mix with preservatives, centrifuge, transfer plasma to a labeled plastic transport tube and refrigerate until time to ship.